Immutep (PRRUF) files Form 6-K on neoadjuvant Efti study tie-up

Rhea-AI Filing Summary

Immutep Limited submitted a Form 6-K as a foreign private issuer, mainly to furnish an exhibit describing a new research collaboration. The exhibit, titled “Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti,” indicates that the company and the George Washington University Cancer Center plan to evaluate neoadjuvant Efti in a cancer setting. This Form 6-K serves as the formal vehicle to provide that collaboration announcement to investors and regulators.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date as September 22, 2025

Commission File Number 001-35428

IMMUTEP LIMITED

(Exact Name as Specified in its Charter)

N/A

(Translation of Registrant’s Name)

Level 32, Australia Square

264 George Street, Sydney

NSW 2000, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐   No ☒

If “Yes” is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

EXHIBIT INDEX

Exhibit		Description of Exhibit
99.1		Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: September 22, 2025

IMMUTEP LIMITED
By:		/s/ Marc Voigt
Name:		Marc Voigt
Title:		Chief Executive Officer

FAQ

What does Immutep Limited (PRRUF) report in this Form 6-K?

The Form 6-K from Immutep Limited furnishes an exhibit announcing a research collaboration with the George Washington University Cancer Center to evaluate neoadjuvant Efti.

Who is Immutep’s collaboration partner mentioned in the filing?

The collaboration partner named in the exhibit is the George Washington University Cancer Center, which will work with Immutep to evaluate neoadjuvant Efti.

What is being evaluated in the Immutep and George Washington University Cancer Center collaboration?

The collaboration described in the exhibit will evaluate neoadjuvant Efti, as referenced in the exhibit title included with the Form 6-K.

What type of SEC document did Immutep Limited (PRRUF) file?

Immutep Limited filed a Form 6-K, which is a report used by foreign private issuers to provide information to the U.S. market under the Securities Exchange Act of 1934.

Who signed the Immutep Form 6-K?

The Form 6-K was signed on behalf of Immutep Limited by Marc Voigt, who is identified as the company’s Chief Executive Officer.

Does this Form 6-K include detailed financial results for Immutep Limited (PRRUF)?

No detailed financial results appear in this content. The filing mainly furnishes an exhibit about a research collaboration to evaluate neoadjuvant Efti.